Published • loading... • Updated
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via ...
Summary by Hastings Tribune
1 Articles
1 Articles
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via ...
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes
·Nebraska, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
